Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Appointed director
Notes underwriting agrmnt
Kura Oncology, Inc. (KURA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Kura Oncology Reports Second Quarter 2023 Financial Results – Enrollment in registration-directed trial of ziftomenib in NPM1-mutant AML continues to outperform projections – – First patients dosed in combination study of ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – Late-breaking clinical data for ziftomenib in NPM1-mutant AML presented at EHA – – Continued evidence of clinical activity observed in trial of tipifarnib plus alpelisib in PIK3CA-dependent HNSCC – – First-in-human study of next-generation FTI KO-2806 to begin in second half of 2023 – – $477 million in cash, equivalents and investments provide runway to mid-2026 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, Aug. 3, 2023– Kura Oncology, Inc. , a clinical-stage biopharmaceutical c..."
08/03/2022 8-K Quarterly results
Docs: "Kura Oncology Reports Second Quarter 2022 Financial Results – Recommended Phase 2 dose for ziftomenib identified, pending FDA review – – Additional 18 patients enrolled in KOMET-001 trial of ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – Preliminary activity observed in KURRENT-HN trial of tipifarnib plus alpelisib in PIK3CA-dependent HNSCC, first patient dosed in HRAS overexpression cohort – – $450 million in cash, cash equivalents and investments provide runway through 2024 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, August 3, 2022 – Kura Oncology, Inc. , a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported second quarter 2022 financial results and..."
05/04/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Kura Oncology Reports Third Quarter 2021 Financial Results – Continued enrollment in Phase 1b study of menin inhibitor KO-539 in NPM1-mutant and KMT2A-rearranged relapsed/refractory AML –"
11/05/2020 8-K Quarterly results
Docs: "Preliminary data for KO-539 accepted for oral presentation at ASH – An abstract reporting preliminary data from KOMET-001, a first-in-human study of the Company’s oral, potent and selective menin inhibitor, KO-539, has been accepted for oral presentation at ASH. The abstract, posted on the ASH website on November 4, 2020, highlighted encouraging safety and tolerability, as well as evidence of anti-leukemic activity as of the data cutoff of August 10, 2020. Kura plans to present a more mature dataset, including data from approximately 10 patients, in the oral presentation at ASH on December 5, 2020, followed by a virtual investor event featuring two of the trial’s investigators. • KO-539 approaching recommended Phase 2 dose, expansion cohorts – Kura remains focused on its goal of rea..."
08/06/2020 8-K Quarterly results
05/04/2020 8-K Quarterly results
11/05/2019 8-K Quarterly results
Docs: "Durable anti-tumor activity in Phase 2 trial of tipifarnib in HRAS mutant HNSCC – Last week, Kura reported updated data from its RUN-HN Phase 2 trial of tipifarnib in HNSCC patients with high HRAS mutant variant allele frequency at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. The preliminary results showed that 10 of the 18 efficacy-evaluable patients achieved a confirmed partial response , for an objective response rate of 56%. In addition, eight patients experienced disease stabilization, including two who achieved an unconfirmed PR, one of whom was awaiting a confirmatory response assessment as of the data cutoff date. The median progression-free survival of the 18 evaluable patients treated with tipifarnib was 6.1 months, compared ..."
08/01/2019 8-K Quarterly results
Docs: "Registration-directed trial of tipifarnib in HRAS mutant HNSCC – Kura continues to execute on its initial registration-directed trial of tipifarnib in HRAS mutant HNSCC. The clinical trial has two cohorts: A non-interventional screening and outcomes cohort and a treatment cohort . AIM-HN is designed to enroll at least 59 evaluable patients with HRAS mutant HNSCC who have received prior platinum-based therapy. AIM-HN initiated in November 2018 and is expected to take approximately two years to fully enroll. • Positive Phase 2 trial of tipifarnib in AITL and CXCL12-driven PTCL – In June 2019, Kura reported positive data from its ongoing Phase 2 trial of tipifarnib in patients with relapsed or refractory PTCL, including clinical proof-of-concept in the trial’s two expansion cohorts: 1)..."
05/07/2019 8-K Quarterly results
Docs: "Registration-directed trial of tipifarnib in HRAS mutant HNSCC – Kura’s global, multi-center, open-label, non-comparative registration-directed trial of tipifarnib continues on track. The clinical trial has two cohorts: A non-interventional screening and outcomes cohort and a treatment cohort . AIM-HN is designed to enroll at least 59 evaluable patients with HRAS mutant HNSCC who have received prior platinum-based therapy. AIM-HN initiated in November 2018 and is expected to take approximately two years to fully enroll. • Farnesylated proteins associated with CXCL12 expression – In April 2019, Kura reported new findings at the American Association for Cancer Research Annual Meeting suggesting that gene expression of the exclusively farnesylated proteins RHOE and PRICKLE2 is strongly..."
08/06/2018 8-K Quarterly results
Docs: "Kura Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update – Update from ongoing Phase 2 trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas to be presented at ESMO 2018 –"
05/08/2018 8-K Quarterly results
Docs: "Kura Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update – Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas on track to initiate in second half of 2018 –"
11/07/2017 8-K Quarterly results
Docs: "Kura Oncology Reports Third Quarter 2017 Financial Results and Provides Corporate Update Management to host webcast and conference call today at 4:30 p.m. ET"
08/07/2017 8-K Quarterly results
Docs: "Kura Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Tipifarnib Phase 2 Study"
05/15/2017 8-K Quarterly results
Docs: "Kura Oncology Reports First Quarter 2017 Operational and Financial Results Management to host webcast and conference call today at 4:30 p.m. EDT"
03/14/2017 8-K Form 8-K - Current report
11/07/2016 8-K Quarterly results
Docs: "Kura Oncology Reports Third Quarter 2016 Financial Results Management to host webcast and conference call today at 1:30 p.m. PST/4:30 p.m. EST"
08/10/2016 8-K Form 8-K - Current report
05/11/2016 8-K Form 8-K - Current report
03/17/2016 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy